In lieu of investments in individual genomics companies, BioChem Pharma Inc. has invested C$30 million (US$21.9 million) in a C$100 million (US$73 million) venture capital fund that will focus on early stage genomics technologies. BCHXF's indirect wholly owned subsidiary, GeneChem Management Inc. will manage the fund, GeneChem Technologies Venture Fund L.P. The fund's mandate is to invest in early-stage academic projects and private or public companies working on genomics and related technologies for human applications.

"We recognize the